Novartis AG v Pharmacor Pty Limited (No 3)

Link copied
Case Copied 69 min read

FEDERAL COURT OF AUSTRALIA

Novartis AG v Pharmacor Pty Limited (No 3) [2024] FCA 1307

File number: NSD 506 of 2023
Judgment of: YATES J
Date of judgment: 13 November 2024
Catchwords:

PATENTS – infringement – standard patent for a pharmaceutical composition containing certain active pharmaceutical ingredients (APIs) – claim construction – whether claim covers a pharmaceutical composition where the API is in the form of a complex in which the ions are associated by non-covalent bonds

PATENTS – identity of the person skilled in the art – where the person skilled in the art is understood as a “team” – discussion of the characteristics of the person skilled in the art    

PATENTS – validity – lack of inventive step – availability of prior art information – whether person skilled in the art could be reasonably expected to have ascertained and regarded as relevant certain prior art publications

PATENTS – validity – lack of inventive step – discussion of the reformulated “Cripps question” – whether obviousness established on the evidence

PATENTS – extension of patent term – whether extension validly granted – whether rectification of the Register of Patents should be ordered

PATENTS – The Last Judgment

Legislation: Patents Act 1990 (Cth) ss 7, 18, 40, 70, 138, 192
Cases cited:

Aktiebolaget Hassle v Alphapharm Pty Limited [2002] HCA 59; 212 CLR 411

Application of Tomlinson (1966) 363 F 2d 928

Aspirating IP Limited v Vision Systems Limited [2010] FCA 1061; 88 IPR 52

AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; 226 FCR 324

AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30; 257 CLR 356

Boehringer Ingelheim Animal Health USA Inc v Intervet International BV [2022] FCAFC 88; 166 IPR 468

Catnic Components v Hill & Smith Ltd [1982] RPC 183

Commissioner of Patents v Ono Pharmaceutical Co. Ltd [2022] FCAFC 39; 291 FCR 1

Crane v Price (1842) 4 Man & G 580

Dow Corning Corporation’s Application [1969] RPC 544

Federal Commissioner of Taxation v Peabody [1994] HCA 43; 181 CLR 359

General Tire & Rubber Co v Firestone Tyre & Rubber Co Ltd [1972] RPC 457

Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft [2014] FCAFC 73; 222 FCR 336

GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) Ltd v Generic Partners Pty Ltd [2018] FCAFC 71; 264 FCR 474

H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70; 177 FCR 151

Hanwha Solutions Corporation v REC Solar Pte Ltd [2023] FCA 1017

Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9

Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (No 2) [2007] HCA 21; 235 CLR 173

MMD Australia Pty Ltd v Camco Engineering Pty Ltd [2024] FCAFC 38

Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd [2020] FCAFC 116; 279 FRC 354

Novartis AG v Pharmacor Pty Limited [2023] FCA 804

Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157

Otsuka Pharmaceutical…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited (No 3) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 1307
Decision Date

CaseChat Overview and Summary

Novartis AG sought to enforce a patent against Pharmacor Pty Limited for alleged infringement. The central dispute involved the interpretation and validity of the claims in a standard patent concerning a pharmaceutical composition with specific active pharmaceutical ingredients. The Federal Court of Australia was tasked with determining whether the patent claims covered certain pharmaceutical compositions and if they were valid and infringed. The court had to construe the claims to ascertain their scope, determine whether the claimed invention was properly disclosed in the patent specification, and assess the validity of the patent by examining the inventive step and sufficiency of disclosure.

The legal issues encompassed the proper construction of the patent claims, particularly whether they extended to pharmaceutical compositions where the active pharmaceutical ingredients were in the form of a complex with ions associated by non-covalent bonds. The court also had to identify the relevant person skilled in the art, considering whether this person should be viewed as an individual or a team, and evaluate whether the skilled person could reasonably have identified and considered relevant prior art. The court further needed to decide if the invention lacked an inventive step and if the patent term extension was validly granted, warranting rectification of the Register of Patents.

In its reasoning, the court determined that the claims were properly construed and did not cover the specific pharmaceutical compositions at issue. The court held that the person skilled in the art should be understood as a team, incorporating collective knowledge and expertise. It found that the prior art was not sufficiently identified and considered by the skilled person, which did not establish a lack of inventive step. The court also concluded that the patent term extension was validly granted, and there was no basis for rectifying the Register of Patents. Consequently, the patent was found to be valid, and no infringement occurred.

The final orders required the parties to submit agreed or competing draft orders by a specified deadline to implement the court's decision.

Orders

Orders of the court

1. The parties bring in agreed or, if not agreed competing, draft orders giving effect to these reasons by no later than 4.00pm on 20 November 2024.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

It follows from this that Pharmacor’s challenge to the validity of claim 1 does not arise for determination. In any event, its challenge based on the grounds that claim 1 is not fairly based on the matter described in the specification, or because the specification does not describe the best method known to Novartis AG of performing the invention, depends on a construction of claim 1 that I do not accept. Further, even if, contrary to my finding, the patent subsists, Pharmacor has not established that claim 1 is invalid for lack of an inventive step.BACKGROUNDThe cardiovascular system The cardiovascular system, which includes the heart and blood vessels, is the continuous circulation of blood which returns through the heart twice. Blood is pumped from the right side of the heart to the lungs where it becomes oxygenated. The oxygenated blood then flows to the left side of the heart where it is pumped around the body through blood vessels to deliver oxygenated blood to organs such as the liver and kidneys. Deoxygenated blood is collected by the veins and returned to the right side of the heart to be pumped back to the lungs. The cardiac cycle refers to the steps that occur in a single heartbeat. Around once a second, the cycle commences with an initial “kick” (a rapid increase in pressure as the blood is ejected from the contraction of the left ventricle of the heart into the aorta) occupying about one‑tenth of the cycle, followed by a longer period of relaxation as the heart refills with blood, occupying approximately nine-tenths of the cycle. Because of this, blood circulation is pulsatile. In a healthy person, the common measurement of blood pressure is expressed as 120/80—meaning, 120 mmHg (the maximum pressure reached in the aorta during maximal ejection from the left ventricle, which is called the systolic blood pressure) and 80 mmHg (the pressure at which the aortic valve opens, which is called the diastolic blood pressure). The performance of the heart and blood vessels can be assessed by reference to “contractility” (the ability of the heart to contract) and the “ejection fraction” (the percentage of blood pumped out of a ventricle during each cardiac cycle). Assessing contractility involves measuring the rate at which pressure develops in the left ventricle and the speed at which blood is ejected from the left ventricle. The ejection fraction is typically measured from the left ventricle. A normal left ventricle ejection fraction in a healthy adult is around >55% (i.e., in each cardiac cycle more than 55% of the blood in the left ventricle is ejected into the aorta and arteries). The ejection fraction is an indirect measure of contractility. Regulatory systems The cardiovascular system is regulated by a number of systems. Two important systems that are particularly relevant to understanding the specification are: (a) the renin‑angiotensin‑aldosterone system (RAAS); and (b) the natriuretic peptide (NP) system. The RAAS

Evidence

Evidence Before The Court

I mention these matters because the specification is not directed simply to the invention as defined in claim 1. It contains other teachings directed to supporting the invention as defined by each of the claims. THE EVIDENCE Novartis called expert evidence from: (a)Professor David Linley Hare OAM. Professor Hare is a Professorial Fellow and cardiologist. He holds Bachelor of Medicine and Bachelor of Surgery degrees and a Diploma in Psychological Medicine from the University of Melbourne. Professor Hare has extensive experience in treating patients with heart failure and hypertension. He has also been involved in cardiovascular research. Professor Hare made two affidavits and provided a joint expert report with Professor Coats (see below).(b)Professor Jonathan Michael White. Professor White is an organic chemist with over 30 years’ experience in synthetic organic chemistry and physical organic chemistry. Professor White holds a Bachelor of Science (Honours, First Class) degree majoring in chemistry and a PhD in chemistry from the University of Canterbury. He has an extensive understanding of the principles of organic synthesis and the analysis of compounds, including the nature and characteristics of different types of bonds that exist between atoms, ions and molecules. Professor White made three affidavits and provided a joint expert report with Professor Roberts and Professor Steed (see below). Novartis also read affidavits from John Fredrick Howards Collins, a partner in Clayton Utz, the solicitors for Novartis. Pharmacor called expert evidence from: (a)Professor Andrew Justin Stewart Coats AO. Professor Coats is a cardiologist. Professor Coats holds Bachelor of Medicine and Bachelor of Surgery degrees from the University of Cambridge and a Master of Arts (Physiological Sciences) degree from the University of Oxford. He also holds a Doctorate of Medicine from the University of Oxford and a Doctorate of Science from Imperial College London. He holds specialist accreditations in Australia and the United Kingdom in general internal medicine and cardiology. He has extensive experience in treating patients with heart failure and hypertension. He has been involved in cardiovascular research. Professor Coats made two affidavits and provided a joint expert report with Professor Hare. (b)Professor Jonathan William Steed. Professor Steed is Professor of Inorganic Chemistry at Durham University. He has over 30 years’ experience in the fields of organic, inorganic and solid-state chemistry. He holds a Bachelor of Science degree majoring in Chemistry (Honours, First Class) and a PhD in Chemistry University College London. His research career has focused on, amongst other things, solid-state chemistry. Professor Steed made two affidavits and provided a joint expert report with Professor Roberts and Professor White.(c)Professor Michael Stephen Roberts: Professor Roberts is a pharmaceutical scientist with over 50 years’ experience working in the fields of drug formulation, drug absorption, pharmacology, toxicology, and pharmacokinetics. He holds Bachelor of Pharmacy degree from the University of Adelaide. He also holds a Master of Science degree in pharmacy, a PhD in pharmaceutical science, and a DSc degree from the University of Sydney. Professor Roberts made two affidavits and provided a joint expert report with Professor Steed and Professor White.(d)Dr George Mokdsi: Dr Mokdsi is an intellectual property analyst and searcher, and a director of The Patent Searcher. Dr Mokdsi has a PhD in chemistry from the University of Sydney. He has expertise in the searching of pharmaceutical patents and scientific literature. Dr Mokdsi made one affidavit.

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established